NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis $11.67 +0.26 (+2.28%) Closing price 09/16/2026 04:00 PM EasternExtended Trading$11.88 +0.21 (+1.76%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AbCellera Biologics Stock (NASDAQ:ABCL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AbCellera Biologics alerts:Sign Up Key Stats Today's Range$11.18▼$11.7350-Day Range$5.25▼$12.5052-Week Range$2.74▼$12.58Volume4.53 million shsAverage Volume4.74 million shsMarket Capitalization$3.58 billionP/E RatioN/ADividend YieldN/APrice Target$12.83Consensus RatingModerate Buy Company Overview AbCellera Biologics Inc. is a biotechnology company that develops antibody-based medicines in partnership with pharmaceutical and biotechnology companies. Its technology platform combines artificial intelligence, machine learning, high-throughput screening, single-cell analysis and other laboratory techniques to identify and evaluate antibody candidates. The company provides integrated antibody discovery and development services, helping partners move from biological targets and immune-cell samples to optimized therapeutic antibody candidates. AbCellera’s work supports drug programs across areas such as oncology, infectious diseases, autoimmune disorders and other conditions. Its platform has also been used in the discovery of antibody treatments for COVID-19, including bamlanivimab, which was developed with Eli Lilly and Company. Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera serves biopharmaceutical partners internationally. Co-founder Carl Hansen has served as the company’s president and chief executive officer. AbCellera’s business model is based on collaborating with partners worldwide and retaining rights to potential medicines discovered through its platform.AI Generated. May Contain Errors. Read More AbCellera Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreABCL MarketRank™: AbCellera Biologics scored higher than 41% of companies evaluated by MarketBeat, and ranked 561st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingAbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for AbCellera Biologics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAbCellera Biologics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AbCellera Biologics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.68) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -21.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -21.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 3.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AbCellera Biologics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.83% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 5.18.Change versus previous monthShort interest in AbCellera Biologics has recently decreased by 15.94%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.94 News SentimentAbCellera Biologics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AbCellera Biologics this week, compared to 4 articles on an average week.Search InterestOnly 12 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders28.40% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbCellera Biologics' insider trading history. Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABCL Stock News HeadlinesAbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026September 16 at 4:05 PM | businesswire.comAbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026September 2, 2026 | businesswire.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 17 at 1:00 AM | Decentralized Masters (Ad)What'sGoing On With AbCellera Biologics Stock On Tuesday?August 25, 2026 | msn.comAre Biotech Stocks The 'Comeback Kid' Of 2026? I Say YesAugust 16, 2026 | seekingalpha.comAbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market OpportunityAugust 15, 2026 | finance.yahoo.comAbCellera Biologics Announces Oversubscribed $200 Million OfferingAugust 13, 2026 | tipranks.comAbCellera Biologics prices oversubscribed $200M offering at $9.75/shareAugust 13, 2026 | msn.comSee More Headlines ABCL Stock Analysis - Frequently Asked Questions How have ABCL shares performed this year? AbCellera Biologics' stock was trading at $3.42 at the start of the year. Since then, ABCL shares have increased by 241.2% and is now trading at $11.67. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) announced its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.02. The firm had revenue of $4.05 million for the quarter, compared to analyst estimates of $7.85 million. AbCellera Biologics had a negative net margin of 248.83% and a negative trailing twelve-month return on equity of 17.49%. Read the conference call transcript. When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $423 million in an initial public offering on Friday, December 11th 2020. The company issued 24,150,000 shares at $17.00-$18.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? Top institutional shareholders of AbCellera Biologics include TD Waterhouse Canada Inc. (3.12%), Bank of America Corp DE (2.00%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.41%) and BlackRock Inc. (1.25%). View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbCellera Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and AUO (AUOTY). Company Calendar Last Earnings8/05/2026Today9/16/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ABCL's financial health is in the Green zone, according to TradeSmith. ABCL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABCL CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees562Year Founded2012Price Target and Rating Average Price Target for AbCellera Biologics$12.83 High Price Target$30.00 Low Price Target$4.00 Potential Upside/Downside+10.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.41 million Net Margins-248.83% Pretax Margin-297.36% Return on Equity-17.49% Return on Assets-12.36% Debt Debt-to-Equity RatioN/A Current Ratio12.77 Quick Ratio12.77 Sales & Book Value Annual Sales$75.13 million Price / Sales47.63 Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book3.61Miscellaneous Outstanding Shares306,610,000Free Float219,533,000Market Cap$3.58 billion OptionableOptionable Beta1.32 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ABCL) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
